Some of the statistical properties of a simple two-stage model of carcinogenesis are explored. The implications of additive treatment effects versus independent treatment effects on the shape of the doseresponse curve are considered. Response that is low-dose linear results in the cases where the mutation rates are affected by dose or in the cases where treatment changes the birth rate/death rate of initiated cells in an additive fashion. Independent treatment effects lead to non-low-dose linear response when the survival of initiated cells is affected by treatment. A computer simulation experiment was performed that examined the ability of animal carcinogenesis data to differentiate between various forms of this simple two-stage model. It is shown that animal carcinogenicity experiments do not contain enough data to adequately describe the difference between these two types of effects.
Introduction
Dose-response models have been used for many years in the quantitative analysis of animal carcinogenesis data. A review of some of the earliest models is given by Krewski and Brown (1) . Recent developments in the areas of cell biology, biochemistry, molecular biology, etc., have led to more complicated mechanistic models of carcinogenesis. These mechanistic models have several advantages over simpler probability models or tolerance distribution models. As these models utilize knowledge ofthe carcinogenic process, they aid in developing improved testing procedures and in explaining a broad range of experimental outcomes. Also, these models generally utilize parameters that have some type of mechanistic interpretation (e.g., mutation rates) and information on these parameters may be available from experiments other than the usual long-term chronic bioassay. These models also have their limitations. Many of these mechanistic parameters are difficult to obtain, requiring specialized biochemical procedures that must be developed for each compound. When information from experiments other than the typical carcinogenicity experiment is available, the inclusion of this information into the risk estimation process is difficult, requiring assumptions that may have questionable biological applicability.
One mechanistic model of carcinogenesis is the multistage model (2) (3) (4) . The original form of this model has been modified to encompass changes in our understanding of the carcinogenic process (3, 5, 6 ). An excellent review of the mathematical development of the multistage model of carcinogenesis is given by Whittemore and Keller (4) . In what follows, a very simple two-stage model of carcinogenesis is studied. Two issues will be discussed: the shape of dose-response curves derived from this simple two-stage model and the ability of animal carcinogenicity data to differentiate between the different shapes.
Clonal Two-Stage Model
The evidence that carcinogenesis is a multistage process is derived from several sources (2, 5, (7) (8) (9) . A simple description of this process is given by the following clonal two-stage model. It is believed that in many cases, the first stage of the carcinogenic process is a mutation (10) (11) (12) . This collection of mutated or initiated cells are allowed to clonally expand by incorporating birth rates and death rates for these cells. Finally, this two-stage model requires a second mutation to transform these initiated cells into malignant cells. Figure 1 illustrates the compartments of this model and displays the notation we will use for the rates discussed above. The In this situation, the term additive is used to indicate that treatment augments an ongoing process. Thus, if treatment induced a proportional increase in either of the two mutation rates in this model, the single parameter w, which will be referred to as the mutation rate, would be expressed using two parameters in the form wo + w1d where d represents the treatment level. Similarly, if treatment caused a proportional change in either the birth rate or the death rate of initiated cells, the model would be modified to include the form yo + -yld. Note that it is not possible to determine whether treatment affects the first mutation or the second when the exposure is over the entire lifetime of the animal. Similarly, if treatment affects the rate of birth and/or death of initiated cells, it is not possible to determine whether that effect is on the birth rate, the death rate or both. This additive clonal two-stage model is given by: Figure 2 illustrates a situation in which the treatment only affects the mutation rates. In terminology used by several authors (13, 15, 16) , agents that act in this manner would be labeled as "initiators." Figure  3 illustrates the dose-response curve for this model after 2 years of exposure. Similarly, letting 0w = 0 and ,Yl = lyJ2, the dose-response curve at 2 years is altered as shown in Figure 4 . An agent that acts in this manner has been referred to as a "promoter." The major difference between Figure 3 and Figure 4 is in the degree of curvature of the dose-response relationship; Figure  3 more closely agrees with a linear function than does A major concern in carcinogenic risk assessment is whether or not a model is low-dose linear. This term is somewhat misused because it is quite easy to show that any continuous function can be approximated by a linear function in a specified small range. What is meant by low-dose linear is that the slope of the dose-response curve at d = 0 is greater than zero. If the slope of the dose-response curve is greater than zero at d = 0, a small increase in dose will result in a proportional increase in risk. On the other hand, if the slope of the dose-response curve at d = 0 is zero, then a small increase in dose will result in virtually no change in risk. For this reason, dose-response models that are low-dose linear generally estimate smaller acceptable exposures than models which are not low-dose linear. Both of the models shown in Figures 3 and 4 (the probability of at least one malignant cell via the first path) and P2(tld) = 1 -S[tld,w02,o12,YO2,Y12] (the probability of at least one malignant cell via the second path). Since it is assumed that all spontaneous mutations occur via the first path, Pl(t) > 0 and that P2(tld = 0) = 0. The probability of at least one malig- (14) on the incidence of adrenal pheochromocytomas in female Fischer 344 rats. In the terninology presented above, this would represent an initiation effect of treatment. As is obvious by this graph, this type of effect results in a low-dose linear model. In Figure 7 , w12 iS set to 0 and 'Y12 = 15, a very strong promotion effect. It is obvious from this plot that an independent promotion effect results in models which are not low-dose linear and have a slope of zero at dose = 0.
In general, when the background tumor rate is small or zero, treatment will affect these models in the same manner as independent treatment effects. That is, initiators will appear to be low-dose linear and promoters will not.
In summary, we see that in most cases, treatment effects in this two-stage model will exhibit low-dose linear behavior. This includes the additive treatment effects described above and any proportional treatment effects on the mutation rate. The only case for which this model displayed nonlinear low-dose behavior was for independent promotional effects.
Utility of Carcinogenesis Data for Determining Mechanism
The results of animal carcinogenicity experiments are used to assess the risk from exposure to environmental agents (17) . To illustrate additional problems with the use of this model, computer simulation of animal carcinogenicity data can be used. The technical details concerning the way in which animal carcinogenicity experiments are simulated has been presented elsewhere (18) It has been suggested that the clonal two-stage model applied to animal carcinogenesis data could be used to make suggestions about the mechanism ofaction of some carcinogens (13, 15, 16) . Judging from Figures 3 and 4 , it seems unlikely that we would be able to differentiate between additive initiation and promotion effects when background response exists. Simulation experiments provide a means to determine if the ability to differentiate between various mechanisms is possible. Basically, data are generated from either a promotion-only model or an initiation-only model. When fitting this model to simulated carcinogenicity data, it is possible to get small promotional effects in the experimental range that have no impact in the low-dose range and vice-versa for initiation effects. To allow for this, the definition of an initiator was modified to include all cases where w, dominates the estimate of added risk in the low-dose range even though yi may be positive (see Appendix). Similarly, the definition of a promoter was modified to allow for the added risk estimate to be dominated by the estimate of -Yl in the low-dose range. Two other outcomes are possible in the simulations; no significantly increased dose response and significantly increased dose response, which results in both w, and yj affecting the estimated low-dose risk. Table 1 shows the percentage of times in 1000 simulated data sets that an initiator is correctly classified. For this table, data were generated assuming an additive treatment effect on wo and assuming -Yl = 0. As the slope of the dose-response curve increases (column 1), our ability to correctly classify initiators improves. However, it is clear from Table 1 that animal carcinogenesis data does not provide enough information to correctly classify initiators, with the possible exception of very steep dose-response curves (w1/wo = 3). When data are generated using an additive promotion effect, As mentioned earlier, one advantage of mechanistic models is that some parameters may be available from sources other than the cancer bioassay. Assuming these parameters are for untreated animals, we see from Tables 2 and 3 that knowledge of one of the spontaneous model parameters does not improve our ability to differentiate between initiation effects and promotion effects.
When the background tumor rate is greater than zero and treatment effects are independent, the ability to differentiate between initiation effects and promotion effects is not improved. In Table 4 , we have generated experiments for which there is only a promotional effect (Y12 > 0, W 12 = 0) using the independent treatment effect model described above. It is clear that even when the promotion effect is very strong, there is a chance that a small initiation effect will dominate the low-dose risk estimates. Again, as is illustrated by Table 5 , knowledge of one of the spontaneous parameters does not noticeably improve the ability of animal carcinogenesis data to differentiate between promoters and initiators.
The examples presented above are for the cases (20, 21) . It is also possible that the treatment could be cytotoxic, reducing the size of the susceptible population and/or increasing the mitotic rate in these cells. It is possible that these mechanisms could play a significant role in the formation of tumors. In general it is believed these mechanisms would result in doseresponse relationships that will not be low-dose linear. As is the case above, this will depend upon whether they are proportional effects and whether these effects are independent or additive.
Despite the problems mentioned above, mechanistic models serve an important role in carcinogenic risk assessment. When one is extrapolating beyond the range of the data, one would like to use a model that contains the largest amount of information available on the process being modeled. In addition, these models are very useful for developing alternative designs and novel experiments to address broader issues in cancer risk assessment. They also provide a conceptual framework in which to think about experimental results and help to combine information from a variety of experiments. However, one should be careful not to overinterpret the parameters arrived at by fitting mechanistic models to animal data.
APPENDIX
As mentioned in the text, the definitions of initiators and promoters were modified for dealing with model estimates from the simulations. For the purposes of risk assessment it is too strict to require that estimated parameters be identically zero before a classification can be made. Instead, since low-dose risk assessment is the goal of our analysis, the definition was modified so that a simulated response was labeled as an initiator if the dose-related mutation parameter (wi) dominated the low-dose risk estimate. This was done by calculating close in value to SO -Sd, then one could conclude that the promotion effect is very strong at low doses. Similarly, SO -Si estimates the added risk for a dose of E using only the initiation effect. A simulated effect was considered to be a low dose initiation effect if (SO -Si)l (So -Sd) -(So -Sp)/(S0 -Sd) > 0.10. That is, the relative initiation effect is 10% larger than the relative promotion effect. Similarly, if this quantity was less than -0.10, the simulated effect was assumed to be a promotion effect. Since, for very low doses, small mutation effects could dominate the added risk estimate, we also considered E = 0.01. The results in Tables 1-3 are forE = 10' and those in Tables 4 and 5 are forE = 0.01.
